Congruence Therapeutics key facts
- Operator of a computationally-driven biotechnology company intended to discover novel drugs.
- It has raised $136.5M; the latest was Later Stage VC ($39.5M) in Mar 2026.
- Notable investors include BDC Capital, OrbiMed, Investissement Quebec, Fonds de solidarite FTQ, Dimension (United States) — 14 tracked in total.
- Status: Privately Held (backing).
Who backs Congruence Therapeutics
14+- ·The complete investor list: 14 names
- ·Watch Congruence Therapeutics: the Monday email on marks, rounds and moves
Congruence Therapeutics funding rounds
No funding rounds for Congruence Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Congruence Therapeutics investors
14 investors are on record for Congruence Therapeutics, including BDC Capital, OrbiMed, Investissement Quebec and Fonds de solidarite FTQ.
About Congruence Therapeutics
Operator of a computationally-driven biotechnology company intended to discover novel drugs. The company uses structural bioinformatics, computational chemistry, and machine learning to design new pharmacological stabilizers at an accelerated pace and scale, providing biotechnology organizations with the ability to correct the pathogenesis of disease with predictive models to identify new pharmaceutical stabilizers for diseases of protein misfolding
- Sector
- Healthcare
- HQ
- Montreal, Canada
- Founded
- 2021
- Employees
- 41
- Website
- congruencetx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Congruence Therapeutics doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.